|
?:abstract
|
-
OBJECTIVE: Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear. Metformin increases the expression of angiotensin converting enzyme 2, a known receptor for severe acute respiratory syndrome coronavirus 2. Data from people with T2DM hospitalized for COVID-19 were used to test the hypothesis that metformin use is associated with improved survival in this population. METHODS: Retrospective analyses were performed on de-identified clinical data from a major hospital in Wuhan, China, that included patients with T2DM hospitalized for COVID-19 during the recent epidemic. One hundred and thirty-one patients diagnosed with COVID-19 and T2DM were used in this study. The primary outcome was mortality. Demographic, clinical characteristics, laboratory data, diabetes medications, and respiratory therapy data were also included in the analysis. RESULTS: Of these 131 patients, 37 used metformin with or without other antidiabetes medications. Among the 37 metformin-taking patients, 35 (94.6%) survived and 2 (5.4%) did not survive. The mortality rates in the metformin-taking group versus the non-metformin group were 5.4% (2/37) versus 22.3% (21/94). Using multivariate analysis, metformin was found to be an independent predictor of survival in this cohort (P = .02). CONCLUSION: This study reveals a significant association between metformin use and survival in people with T2DM diagnosed with COVID-19. These clinical data are consistent with potential benefits of the use of metformin for COVID-19 patients with T2DM.
-
Objective: Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear Metformin increases the expression of angiotensin converting enzyme 2, a known receptor for severe acute respiratory syndrome coronavirus 2 Data from people with T2DM hospitalized for COVID-19 were used to test the hypothesis that metformin use is associated with improved survival in this population Methods: Retrospective analyses were performed on de-identified clinical data from a major hospital in Wuhan, China, that included patients with T2DM hospitalized for COVID-19 during the recent epidemic One hundred and thirty-one patients diagnosed with COVID-19 and T2DM were used in this study The primary outcome was mortality Demographic, clinical characteristics, laboratory data, diabetes medications, and respiratory therapy data were also included in the analysis Results: Of these 131 patients, 37 used metformin with or without other antidiabetes medications Among the 37 metformin-taking patients, 35 (94 6%) survived and 2 (5 4%) did not survive The mortality rates in the metformin-taking group versus the non-metformin group were 5 4% (2/37) versus 22 3% (21/94) Using multivariate analysis, metformin was found to be an independent predictor of survival in this cohort (P = 02) Conclusion: This study reveals a significant association between metformin use and survival in people with T2DM diagnosed with COVID-19 These clinical data are consistent with potential benefits of the use of metformin for COVID-19 patients with T2DM Abbreviations: ACE2 = angiotensin-converting enzyme 2;AMPK = AMP-activated protein kinase;BMI = body mass index;COVID-19 = coronavirus disease 2019;SARSCoV-2 = severe acute respiratory syndrome coronavirus 2;T2DM = type 2 diabetes mellitus
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}